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Abstract
Background: Bright-blood and black-blood cardiovascular magnetic resonance (CMR) techniques are frequently
employed together during a clinical exam because of their complementary features. While valuable, existing
black-blood CMR approaches are flow dependent and prone to failure. We aim to assess the effectiveness
and reliability of ferumoxytol enhanced (FE) Half-Fourier Single-shot Turbo Spin-echo (HASTE) imaging without
magnetization preparation pulses to yield uniform intra-luminal blood signal suppression by comparing FE-HASTE with
pre-ferumoxytol HASTE imaging.
Methods: This study was IRB-approved and HIPAA compliant. Consecutive patients who were referred for FE-CMR
between June 2013 and February 2017 were enrolled. Qualitative image scores reflecting the degree and reliability of
blood signal suppression were based on a 3-point Likert scale, with 3 reflecting perfect suppression. For quantitative
evaluation, homogeneity indices (defined as standard deviation of the left atrial signal intensity) and signal-to-noise
ratios (SNR) for vascular lumens and cardiac chambers were measured.
Results: Of the 340 unique patients who underwent FE-CMR, HASTE was performed in 257. Ninety-three patients had
both pre-ferumoxytol HASTE and FE-HASTE, and were included in this analysis. Qualitative image scores reflecting the
degree and reliability of blood signal suppression were significantly higher for FE-HASTE images (2.9 [IQR 2.8–3.0] vs 1.8
[IQR 1.6–2.1], p < 0.001). Inter-reader agreement was moderate (k = 0.50, 95% CI 0.45–0.55). Blood signal suppression
was more complete on FE-HASTE images than on pre-ferumoxytol HASTE, as indicated by lower mean homogeneity
indices (24.5 [IQR 18.0–32.8] vs 108.0 [IQR 65.0–170.4], p < 0.001) and lower blood pool SNR for all regions
(5.6 [IQR 3.2–10.0] vs 21.5 [IQR 12.5–39.4], p < 0.001).
Conclusion: FE-HASTE black-blood imaging offers an effective, reliable, and simple approach for flow
independent blood signal suppression. The technique holds promise as a fast and routine complement to bright-blood
cardiovascular imaging with ferumoxytol.
Keywords: USPIO, Ferumoxytol, Magnetic resonance imaging, Black-blood imaging, HASTE
Background
Black-blood cardiovascular magnetic resonance (CMR)
imaging is important for depiction of vessel wall and
intra-cardiac abnormalities. While the intensity and uni-
formity of luminal enhancement serve as the benchmark
for bright blood CMR angiography, the completeness and
uniformity of blood pool signal suppression set the
complementary standard for black-blood imaging. A var-
iety of strategies have been employed to suppress the
blood signal [1], but most are to some degree flow
dependent [2]. As a result, slow or inconsistent blood flow
can result in persistence of signal within a patent vessel or
cardiac chamber, mimicking a mass or thrombus.
Because of its speed, simplicity, and resistance to mo-
tion artifact, Half-Fourier Single-shot Turbo Spin-echo
(HASTE) [3] imaging is widely used to complement
bright blood techniques in CMR imaging [1]. The long
echo train of HASTE (and related multi-echo spin echo
techniques) supports efficient signal suppression for
moderate to high velocity flow, but signal from slowly
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flowing blood can persist. For this reason, a dual inver-
sion recovery magnetization preparation scheme is typic-
ally used to null the magnetization of blood which
enters the imaging slice between the inversion and the
readout [4]. Dual inversion recovery is effective as an ad-
junct for many black-blood applications and remains the
most widely used scheme for black-blood conditioning
of the great vessels and cardiac chambers. However, be-
cause of variable inflow speeds, electrocardiographic
(ECG) gating with patient-specific adjustment of timing
and imaging parameters may be necessary. Further-
more, for certain slice orientations and imaging pa-
rameters, timing conflicts within the cardiac cycle
may undermine achievable image resolution or blood
suppression, particularly in vessels with slow flow.
Therefore, a flow-independent black-blood CMR tech-
nique would be desirable.
Recently, ferumoxytol has re-surfaced as an attractive
CMR contrast agent [5, 6]. Although ferumoxytol is ap-
proved by the U.S. Food and Drug Administration (FDA)
for intravenous treatment of iron deficiency anemia in
adults with kidney disease, its pharmacokinetics and po-
tent r1 and r2 effects (r1 = 15 mM
−1 s−1, r2 = 89 mM
−1 s-1
at 1.5 T) [6, 7] can be exploited to support both bright
blood angiography and flow independent, post-contrast
black-blood imaging.
The purpose of our study is to evaluate the potential
of ferumoxytol to generate reliable, flow independent,
black-blood HASTE images, as a complement to bright-
blood CMR angiography of the thorax, without the need
for any magnetization preparation schemes, by compar-
ing it with pre-ferumoxytol HASTE imaging.
Methods
Study population
This is a retrospective analysis of prospectively enrolled
patients. All study procedures were approved by the
local institutional review board and were compliant
with the Health Insurance Portability and Account-
ability Act. Written informed consent was obtained
from all patients or from their legal guardians. Con-
secutive patients age ≥ 3 years who were referred for
ferumoxytol-enhanced (FE) magnetic resonance angio-
gram (MRA) from June 2013 to February 2017 and
who had black-blood CMR were enrolled (n = 257).
Figure 1 outlines the final patient population included
in the analysis.
Image acquisition
Examinations were performed either on a 3 T (TIM
Trio [n = 161], Prisma Fit [n = 42], Skyra [n = 23];
Siemens Healthineers, Erlangen, Germany) or a 1.5 T
(Avanto [n = 31]; Siemens Healthineers) whole-body
system. A combination of phased array body coils,
spine coils, head and neck coils or extremity coils
were used depending on patient size.
Following initial localizer images, non-breath held
HASTE images were acquired in the coronal plane [1, 8].
Typical acquisition parameters are outlined in Table 1. A
dual inversion recovery, black blood magnetization prep-
aration scheme was employed, but in most cases without
ECG gating, such that the inflow time was not synchro-
nized with or consistent within the cardiac cycle. The time
between adjacent slice acquisitions (repetition time) was
fixed at 3.0 s at 1.5 T and 4.0 s at 3 T. The reason for the
longer than minimum repetition time was to allow for
magnetization recovery within all tissues and to prevent
cross talk and potential saturation between moving struc-
tures of adjacent slices. In one patient with a suspected left
atrial mass on echocardiography, ECG gated pre-
ferumoxytol HASTE imaging was performed in multiple
planes, followed by post-ferumoxytol HASTE imaging.
Typical slice thickness in adults was 7 mm at 1.5 T and
6 mm at 3 T. Stock ferumoxytol was diluted 6X –10X
and administered as a slow infusion to a total dose of
4 mg /kg, as previously described [9]. Subsequently,
breath-held, bright-blood, three-dimensional (3D) CMR
Fig. 1 Flowchart of study population
Table 1 Representative technical parameters for coronal HASTE
3 Tesla 1.5 Tesla
Echo spacing (ms) 4.22 4.04
Echo time (ms) 68 51
Echo train length 123 98
Flip angle (°) 160 160
Bandwidth (Hz) 574 751
Acquisition matrix 512 × 374 512 × 358
Field of view (mm2) 500 × 374 500 × 378
Slice thickness (mm)a 6 7
In-plane resolution (mm2) 1.0 × 1.1 1.0 × 1.4
aFor small children, the similar parameters were used with an effective slice
thickness of 4 mm without interslice gaps
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angiography was acquired during the steady state distribu-
tion of ferumoxytol. FE-HASTE images were acquired
with identical parameters to the pre-ferumoxytol HASTE
images, but without the dual inversion magnetization
preparation scheme. All black-blood images were acquired
during quiet breathing.
Image analysis
To qualitatively assess the effectiveness and reliability of
blood signal suppression, two readers (T.Y. and E.A.P,
each with 2 and 11 years of cardiovascular imaging
experience, respectively) independently reviewed the
pre-ferumoxytol and FE-HASTE images using a com-
mercially available software platform (OsiriX, Pixmeo,
Bernex, Switzerland). Images were de-identified and
presented to reviewers in random order. The datasets
were scored using a 3-point Likert grading scale: 3 =
complete suppression of the blood signal within the vas-
cular lumen on all slices; 2 = persistent, bright-blood signal
within some part of the lumen on one or more slices; and
1 = persistent, bright-blood signal within a considerable
part of the lumen on many or all slices. Ten cardiovascu-
lar regions within the chest cavity were scored: superior
vena cava, both atria, both ventricles, the pulmonary
trunk, the right and left pulmonary arteries, and the mid-
ascending and mid-descending thoracic aorta. A final
image quality score was calculated for each region by aver-
aging the results of primary readers. In cases where the
scores differed by 2 points between reader 1 and 2, a third
reader (K.L.N., 5 years cardiovascular imaging experience)
served as the consensus reader.
In patients with both pre-ferumoxytol and FE-HASTE
images (n = 93), quantitative proxies of blood signal sup-
pression were determined by calculating the signal-to-
noise ratios (SNR) and generating a homogeneity index
for each image dataset. Circular regions of interest
(ROIs) measuring at least 1.0 cm2 were drawn in the
blood pool of the vascular lumen on coronal images.
Coronal HASTE image datasets were chosen because 1)
all 93 patients had at least coronal HASTE datasets and
2) the coronal datasets represent the orientation in
which all of the cardiovascular ROIs were included. Ten
representative vascular and intra-cardiac regions were
scored: superior vena cava, both atria, both ventricles,
pulmonary trunk, right and left pulmonary arteries, as-
cending aorta, and descending thoracic aorta. Image
noise was determined by averaging the standard devi-
ation of four ROIs drawn in the background air located
within the image field of view. SNRs for each region
were calculated by dividing signal intensities by image
noise. The homogeneity index reflecting blood signal
suppression was defined as the standard deviation of sig-
nal in the left atrium. Lower homogeneity indices reflect
greater homogeneous suppression of blood signal in the
vascular lumen. The contrast-to-noise ratio (CNR) was
calculated as the difference between the mean left ven-
tricular signal intensity of the blood pool and myocar-
dium divided by the standard deviation of noise in air.
Statistical analysis
Data were tested for normality using the D’Agostino-
Pearson test and log transformed where needed. De-
scriptive statistics are expressed as means and standard
deviations (SD) or medians and interquartiles (IQR) or
as absolutes and percentages. The SNR for both HASTE
datasets were compared using analysis of variance
(ANOVA) for repeated measurements. Image noise and
CNRs were compared using the Wilcoxon-signed rank
sum test for paired samples. To evaluate for inter-reader
agreement, a kappa (k) value was calculated for qualita-
tive image scores: poor (k < 0.20), fair (k = 0.21–0.40),
moderate (k = 0.41–0.60), good (k = 0.61–0.80), and ex-
cellent (k = 0.81–1.00). Analyses were performed using
MedCalc (Version 16.8.4, Belgium). Two-tailed p values
less than 0.05 were considered statistically significant
and Bonferroni corrected where appropriate.
Results
Of the 340 patients who underwent FE-CMR between
June 2013 to February 2017, a total of 257 patients (age
49 [IQR 16–67] years, 46% females) were ≥3 years old
and had black-blood HASTE imaging. Ninety-three pa-
tients had both pre-ferumoxytol and FE-HASTE im-
aging. Characterization of the study population and
clinical indications are outlined in Fig. 1 and Table 2, re-
spectively. All studies were completed successfully and
without major adverse events.
Qualitative analysis
Compared to pre-ferumoxytol HASTE, the image quality
scores reflecting effectiveness and reliability of blood sig-
nal suppression for FE-HASTE images were significantly
higher (p < 0.001, Fig. 2). Using a 3-point Likert scale with
grade 3 representing complete and uniform blood signal
suppression, FE- HASTE images had an overall image
quality score of 2.9 (IQR 2.8–3.0). The overall image qual-
ity score for pre-ferumoxytol HASTE was 1.8 (IQR 1.6–
2.1). Inter-reader agreement was moderate (k = 0.50, 95%
CI 0.45–0.55).
Figures 3 and 4 provide comparative multislice exam-
ples of pre-ferumoxytol HASTE and FE-HASTE images.
Both patients in Figs. 3 and 4 have critical aortic stenosis
and had FE-CMR in the setting of renal impairment.
Pre-ferumoxytol HASTE images (Fig. 3 and Fig. 4, upper
panel, a-c) show incomplete and variable luminal signal
suppression across all three coronal slices. In contrast,
FE-HASTE images (Fig. 3 and Fig. 4, lower panel, a-c)
demonstrate uniform and complete luminal blood signal
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suppression across multiple slices. Complex atheroscler-
otic plaques can be confidently visualized on T2-weighted
FE-HASTE image (Fig. 3a, lower panel, white arrow). Des-
pite the severely dilated left atrium and differences in the
flow pattern between the great vessels and the left atrium,
there is uniform blood signal suppression on FE-HASTE
images in all structures (Fig. 3, lower panel, a-c). Note the
sharp left atrial myocardial edge definition on FE-HASTE
images (Fig. 3b-c, lower panel). Although there is slight
blurring of the myocardial edge in Fig. 4 (lower panel), the
luminal blood signal suppression is uniform.
Two patients with abdominal aneurysms post endo-
vascular repair are presented in Figs. 5 and 6. In both
examples, the complementarity of black blood FE-
HASTE and bright-blood 3D CMR angiography was
helpful for demonstrating stent patency, characterizing
the aneurysm sac, and determining whether an endoleak
was present. In Fig. 5, FE-HASTE allowed for high
contrast discrimination between perfused lumen and
thrombus. The lack of enhancement within the
aneurysm sac suggests the absence of an endoleak. Con-
versely, the combination of FE-HASTE and bright-blood
CMR angiogram in Fig. 6 showed near circumferential
contrast leakage into the aneurysm sac, suggesting a
Type II endoleak. The complementarity of FE-HASTE
and bright-blood CMR angiogram also allowed for
confident identification of diffuse, eccentric, and ulcer-
ated atherosclerotic plaques along the aorta. Notable is
Table 2 Patient characteristics and clinical indicationsa
All with HASTE
(n = 257)
Pre-FE
HASTE
(n = 121)
Post-FE
HASTE
(n = 229)
Pre- and post-FE
HASTE
(n = 93)
Age, y 49 (16–67) 39 (13–65) 48 (16–67) 44 (16–67)
Gender (female) 118 (46%) 52 (43%) 95 (41%) 40 (43%)
Pre-CMR creatinine (mg/dL) 1.9 (1.2–2.9) 1.9 (1.0–3.0) 1.9 (0.99–2.8) 1.7 (0.95–2.85)
Clinical indications
Aneurysm /dissection 18 (8%) 6 (5%) 18 (8%) 6 (6%)
AVMs 2 (1%) 0 2 (1%) 0
CHD 40 (16%) 15 (12%) 36 (16%) 11 (12%)
Embolus /thrombus 15 (6%) 7 (6%) 14 (6%) 6 (6%)
Interventional planning 28 (11%) 16 (13%) 26 (11%) 14 (15%)
Mass 19 (7%) 13 (11%) 19 (8%) 13 (14%)
Other 10 (4%) 4 (3%) 9 (4%) 3 (3%)
Placenta 4 (2%) 4 (3%) 4 (2%) 4 (4%)
Post-renal transplant 21 (8%) 12 (10%) 20 (9%) 11 (12%)
Pre-renal transplant 12 (5%) 6 (5%) 8 (3%) 2 (2%)
Vascular mapping 22 (9%) 12 (10%) 14 (6%) 4 (4%)
Vascular thrombosis 66 (26%) 26 (21%) 59 (26%) 19 (20%)
AVMs arteriovenous malformations, CHD congenital heart disease, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FE ferumoxytol enhanced,
y years
aValues are reported as median and interquartile range or absolutes and frequencies
Fig. 2 Qualitative comparison between pre-ferumoxytol HASTE and
FE-HASTE images. A 3-point Likert grading scale was employed:
3 = complete suppression of the blood signal within the vascular
lumen on all slices; 2 = persistent, bright blood signal within some
part of the lumen on one or more slices; and 1 = persistent, bright
blood signal within a considerable part of the lumen on many or all
slices. Compared to pre-ferumoxytol HASTE images, the mean image
quality scores for all 10 cardiovascular regions on FE-HASTE images
were significantly higher (p < 0.001). AscAo ascending aorta; DscAo
descending aorta; LA left atrium; LPA left pulmonary artery; LV left
ventricle; MPA main pulmonary artery; RA right atrium; RPA right
pulmonary artery; RV right ventricle; SVC superior vena cava
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the uniform and complete blood signal suppression
depicted on the FE-HASTE images.
The effectiveness of FE-HASTE is further illustrated in
Fig. 7 and Fig. 8. In Fig. 7, FE-CMR was performed to
evaluate known coronary aneurysms in a 4-year old child
with Kawasaki disease. On pre-ferumoxytol HASTE im-
ages, the thrombosed portion (Fig. 7, red T) of the left cor-
onary artery aneurysm and the perfused lumen have
similar signal. However, blood signal suppression on FE-
HASTE clearly differentiated the perfused lumen from the
superior thrombosed portion (Fig. 7, green arrows). These
findings correlate closely with the bright-blood CMR
angiogram. In the setting of cardiomegaly and very slow
flow, FE-HASTE images provided more reliable and
complete blood signal suppression in the left atrium
(Fig. 8). ECG-gating during pre-ferumoxytol HASTE im-
aging (Fig. 8, panel b) failed to provide effective blood sig-
nal suppression whereas FE-HASTE succeeded fully, even
without ECG-gating.
Quantitative analysis
Compared to pre-ferumoxytol HASTE images, intra-
luminal blood signal suppression was more effective on
FE-HASTE (Table 3). The median homogeneity index
for FE-HASTE images was at least five times lower than
pre-ferumoxytol HASTE images (p < 0.001), indicating
more effective signal suppression post-ferumoxytol.
Similarly, the mean SNR for all ten cardiovascular re-
gions (superior vena cava, both atria, both ventricles,
pulmonary trunk, right and left pulmonary arteries,
Fig. 3 Pre- and post-ferumoxytol coronal CMR images (3 T) belonging to a 94-year old male with critical aortic stenosis who had vascular mapping
prior to transcatheter aortic valve replacement. Pre-ferumoxytol HASTE images (a-c, upper panel) illustrate poor blood signal suppression. FE-HASTE
images (a-c, lower panel) at approximately the same region demonstrate uniform blood signal suppression in all vascular regions and intra-cardiac
chambers within the imaged field of view. A multi-slice comparison of pre-ferumoxytol HASTE and FE-HASTE images is available as Additional file 1:
Video S1. Thin scallops of the mitral valve (b, lower panel) are well depicted against the uniformly dark left atrium. Atherosclerotic plaques along the
vessel wall of the transverse aortic arch (a, lower panel, white arrow) are present. Ao aorta; LA left atrium; RA right atrium
Fig. 4 Pre and post-ferumoxytol coronal CMR images (3 T) belonging to a 93-year-old female with critical aortic stenosis who had FE-CMR for
vascular mapping in the setting of renal impairment. Pre-ferumoxytol HASTE images (image quality score 1–2) illustrate inconsistent blood signal
suppression across multiple slices (upper panel, a-c). The blood signal in FE HASTE images (image quality 3) is consistently and uniformly
suppressed in both vascular lumen and intra-cardiac chambers and across multiple slices (lower panel, a-c) compared to pre-ferumoxytol HASTE
images. Ao aorta; LA left atrium; RA right atrium; RPA right pulmonary artery
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ascending aorta, and descending thoracic aorta) was sig-
nificantly lower for FE-HASTE images (5.6 [IQR 3.2–
10.0] vs 21.5 [IQR 12.5–39.4], p < 0.001). Comparison of
SNR for each region is outlined in Table 3. The CNR for
FE-HASTE images (28.3 [IQR 16.6–46.8]) was higher
than pre-ferumoxytol (20.5 [IQR 10.9–42.9]), but this
was not statistically significant (p = 0.14).
Discussion
Our study demonstrates that FE-HASTE is a simple and
effective technique that overcomes many limitations asso-
ciated with conventional black-blood imaging. FE-HASTE
produced reliable, flow independent, uniform suppression
of blood signal in the vascular lumen and cardiac cham-
bers. Compared to pre-ferumoxytol HASTE, FE-HASTE
yielded more consistent and greater homogeneity in blood
signal suppression. In conventional black-blood imaging,
the effectiveness of dual inversion is attributable to the
longer duration available for inflow of the out-of-slice
inverted spins into the imaged volume. With the use of
ECG gating and appropriate adjustment of the inflow time
within the cardiac cycle, the effectiveness of blood signal
suppression can be increased. However, the requirement
for cardiac gating imposes limits on the duration of the
image acquisition window and on spatial resolution, par-
ticularly for slow flow where the inflow time may occupy a
substantial portion of the cardiac cycle. Further, ECG gating
at 3 T can be problematic and prone to inconsistency.
In our study, the dual inversion module of the pre-
ferumoxytol HASTE images was in most cases posi-
tioned randomly within the cardiac cycle and this may
help explain the frequent persistence of intravascular
signal. It is well recognized that with pulsatile blood
flow, the image acquisition window may encompass any-
where from maximum velocity to zero velocity flow on
various slices. Therefore, ours was not a comparison be-
tween an optimal pre-ferumoxytol dual inversion
HASTE and FE-HASTE, but rather a study of how well
FE-HASTE, with parameters chosen to provide high
resolution images and prevent inter-slice cross-talk, sup-
ports complete blood signal suppression without any
magnetization preparation schemes. That said, even with
ECG gating, dual inversion black blood imaging may fail
if timing is not optimal or if flow is very slow, as we
found in the patient illustrated in Fig. 8.
Blood signal suppression with ferumoxytol is inde-
pendent of blood flow because, beyond a threshold TE,
the blood signal will decay because of its T2. In our
study, the TEs employed at both 1.5 T and 3 T were
clearly at or beyond the minimum to ensure full blood
signal suppression, although we did not explore what
the threshold minimum TE was. Our study confirmed
that, with appropriate T2 weighting, FE-HASTE can be
leveraged to complement bright-blood CMR for
characterization of cardiovascular pathology.
Multiple strategies have been explored for blood signal
suppression in MRI, including spatial presaturation, long
train radiofrequency pulses such as RARE (rapid acquisition
with relaxation enhancement) [10], inversion recovery
magnetization preparation techniques [4, 11], or T2* short-
ening of deoxygenated blood (susceptibility weighted im-
aging). Other black-blood techniques and their variants such
as presaturation of inflowing blood by slab-selective radiofre-
quency pulses [12], motion-sensitizing magnetization
preparation gradient echo sequences [13], multislice
motion-sensitized driven-equilibrium (MSDE) turbo spin-
echo sequences [14], free breath 3D whole heart MSDE [15],
and radial steady-state free precession [16] have been also
been introduced. Despite these efforts, black-blood imaging
remains challenging in clinical practice due to troublesome
artifacts and flow dependency. Frequently, sufficient image
quality can be achieved through selection of imaging
parameters on an individualized patient basis and is influ-
enced by the skill and experience of clinicians and technolo-
gists. With FE-HASTE, customized imaging parameters and
Fig. 5 Ferumoxytol enhanced (FE) coronal and axial CMR images
(3 T) belonging to a 71-year-old male with an infrarenal abdominal
aortic aneurysm post endovascular aorto-bifemoral stent repair.
Ferumoxytol CMR was performed to evaluate for endoleak in the
setting of renal impairment. Coronal and axial bright blood high
resolution CMR angiogram (a, d) and FE-HASTE (b, e) images
demonstrate a widely patent stent graft (white arrowhead) without
endoleak. Note the contrasting intraluminal bright blood signal
compared to uniformly dark blood signal suppression in all vascular
lumens and intra-cardiac chambers (b, e, Additional file 2: Video S2).
Thin aortic valve leaflets are clearly depicted (b). FE-HASTE depicts
thrombosis of the aneurysm sac (asterisk, b and e), which is located
outside of the endograft. 3D color volume rendered bright blood
CMR angiogram (c, Additional file 3: Video S3) illustrates the
relationship between the thrombosed aneurysm sac (white arrows)
and the endograft
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Fig. 6 Post-ferumoxytol 3D CMR angiogram multiplanar reformat (a, c) and T2 FE-HASTE (b, d) coronal CMR images (3 T) belonging to an 85-year
old male with infrarenal abdominal aortic aneurysm post endovascular aorto and bilateral iliac stent graft repair. The CMR exam was performed
to evaluate for endoleak. There is diffuse atherosclerosis of the transverse and abdominal aorta with eccentric and ulcerated plaques (a-b, white arrow;
Additional file 4: Video S4). An incidental heterogeneous lesion with serpiginous border (a-b, blue arrow) is present in the right middle
lobe and is well demarcated on FE-HASTE. Coronal FE-HASTE (b, d) demonstrates uniformly suppressed blood signal throughout the
lumen. The aneurysm sac (c-e, white arrows) has circumferential contrast leakage (c-d), suggestive of a Type II endoleak. Relationships
between the endoleak (e, white arrow, segmented green) and stent grafts are depicted on the 3D color volume rendered bright blood
CMR angiogram image (e). Compared to the bright blood CMR angiogram image (c, green arrow), the intra-luminal blood signal is
completely suppressed in the patent iliac stent graft (d, green arrow). Comparison of aortic vessel wall characteristics and endoleak tissue
characteristics on FE-HASTE and bright blood 3D CMR angiogram is available as Additional file 5: Video S5. LA, left atrium; MPR,
multiplanar reformat
Fig. 7 Pre- and post-ferumoxytol CMR images (3 T) belonging to a 4-year-old girl with Kawasaki disease. CMR was performed to evaluate left and
right coronary aneurysms. Compared to pre-ferumoxytol HASTE images, excellent blood signal suppression of intracardiac chambers and vascular
segments is demonstrated on FE-HASTE images. The thrombosed portion of the left coronary aneurysm (T) and the lumen (green arrows) are
well-demarcated on FE-HASTE and 3D high resolution CMR angiogram images. The distinction between the partially thrombosed coronary
aneurysm and the perfused lumen is not well depicted due to complex flow patterns on pre-ferumoxytol HASTE
Nguyen et al. Journal of Cardiovascular Magnetic Resonance  (2017) 19:106 Page 7 of 10
magnetization preparation schemes are not required for ef-
fective blood signal suppression, and less restrictive parame-
ters can be prescribed to optimize other aspects of image
quality. Based on our findings, FE-HASTE is a simple strat-
egy for discrimination between flow artifact and true vessel
wall pathology such as thrombus, tumor, or plaque.
Although ferumoxytol is FDA approved for treatment
of iron deficiency anemia in adults with kidney disease,
it has several promising attributes for diagnostic CMR
imaging [5, 6, 17, 18]. First, unlike gadolinium-based
contrast agents (GBCAs), ferumoxytol is not cleared by
the kidneys, but is metabolized by the reticuloentholelial
system and the iron core is incorporated into the body
for biologic use. Second, although the longitudinal r1
relaxivity of ferumoxytol is similar to gadofosveset, its
intravascular half-life is substantially longer (> 15 h).
With a molecular weight of 750 kD and particle size of
30 nm, ferumoxytol has excellent fidelity as an intravas-
cular contrast agent with both strong T1 and T2* short-
ening effects [7]. The dual potential of ferumoxytol was
previously highlighted by Li et al. [19] in a pilot study of
lower extremity deep venous thrombosis. With the ex-
ception of an abstract by Vu AT et al. describing feru-
moxytol black-blood cine imaging [20], the more general
use of ferumoxytol as a black-blood imaging agent has
not previously been described.
A recent FDA warning highlighted the occurrence of
rare, but serious hypersensitivity reactions associated
with the therapeutic use of ferumoxytol [21], some of
which were associated with fatal outcomes. Based on
therapeutic use data from post-marketing trials [22–26],
the calculated aggregate risk of anaphylactic reaction is
0.03%. Suggestions to minimize hypersensitivity reac-
tions include dilution and slow infusion. Monitoring of
vital signs up to 30 min post-infusion is also recom-
mended and should be standard practice. Compared to
other USPIOs, the outer carbohydrate shell of ferumoxy-
tol was designed to have lower free-iron release [27], de-
creased immunologic allergic reaction, and an improved
safety profile [28]. To date, no severe adverse events
Fig. 8 Pre-ferumoxytol ECG-gated HASTE and post-ferumoxytol
HASTE CMR images without ECG-gating (3 T) belong to a 71-year-
old female with dilated cardiomyopathy and bouts of sustained
ventricular tachycardia (VT). FE-CMR was ordered to delineate a
possible left atrial (LA) mass prior to undergoing VT ablation. Real-
time cine FE-CMR images (panel a) demonstrate a large, sessile,
immobile mass (green arrows) in the posterolateral wall of a severely
dilated left atrium (red arrows). Compared to ECG-gated pre-
ferumoxytol HASTE imaging (panel b), FE-HASTE CMR (panel c and
d) achieved more complete and homogenous blood signal suppression,
which enabled confident and definitive diagnosis of a left atrial mass
(green arrows). The morphologic appearance of the left atrial mass on
FE-HASTE CMR correlated well with findings on bright-blood real-time
cine imaging (panel a; panel d, center image). Ao, aorta; LV, left ventricle;
RV, right ventricle
Table 3 Comparison of SNR measurements as a proxy for
uniform intra-luminal blood signal suppression (n = 93)
Pre-FE
HASTE DIR
Post-FE
HASTE
P value
Image noise 10.0 (6.7–16.5) 9.7 (6.2–15.1) 0.344*
Homogeneity index 108.0 (65.0–170.4) 24.5 (18.0–32.8) <0.001*
Signal-to-noise ratio (SNR)
Overall 21.5 (12.5–39.4) 5.6 (3.2–10.0) <0.001**
SVC 11.2 (5.6–23.0) 6.2 (3.5–13.0) <0.001**
RA 11.3 (5.1–23.6) 3.3 (2.2–6.2) <0.001**
RV 6.4 (2.7–12.3) 2.7 (1.6–6.0) <0.001**
LA 27.5 (10.8–47.0) 4.3 (2.4–7.1) <0.001**
LV 22.4 (5.1–44.3) 3.7 (2.0–5.6) <0.001**
MPA 18.5 (8.1–38.0) 6.2 (2.9–10.9) <0.001**
RPA 22.3 (6.9–37.2) 5.4 (2.9–12.3) <0.001**
LPA 22.0 (8.0–47.1) 6.1 (3.4–11.7) <0.001**
Asc Ao 12.4 (5.0–29.6) 5.1 (2.9–9.2) <0.001**
Dsc Ao 33.2 (15.3–67.6) 6.9 (3.4–15.1) <0.001**
Values are reported as median and interquartile range
Asc Ao ascending aorta, DIR double-inversion recovery, Dsc Ao descending
aorta, FE ferumoxytol enhanced, LA, left atrium, LPA left pulmonary artery, LV
left ventricle, MPA main pulmonary artery, RA right atrium, RPA right pulmonary
artery, RV right ventricle, SNR signal-to-noise ratio, SVC superior vena cava
*Wilcoxon rank sum test; **ANOVA for repeated measures
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have been directly associated with the diagnostic use of
ferumoxytol CMR in both small and large cohort single-
center safety studies [9, 29–31].
Our study has several limitations. First, although im-
ages were evaluated in a blind and random way, the ap-
parent difference in the uniformity of the blood signal
suppression on FE-HASTE images made it challenging
to truly blind the readers. Second, not all images re-
ceived perfect image quality scores even though blood
signal suppression was excellent on FE-HASTE images.
This observation may relate to the intrinsic limitations
of HASTE imaging, and also the lack of cardiac gating
which may result in occasional blurring along vessel or
endocardial borders. However, black-blood imaging is
rarely used alone, but in conjunction with bright blood
imaging techniques, which is where the complementary
duality of FE imaging may be of considerable value. Our
study was also not designed to assess the diagnostic ac-
curacy of FE-HASTE, but rather to gauge its effective-
ness for flow independent blood signal suppression.
More extensive work will be required to address the
broader question of diagnostic accuracy. Lastly, because
of ferumoxytol’s long intravascular half-life, imagers need
to be aware that ferumoxytol may influence CMR tissue
contrast for days or weeks, and should interpret follow up
studies appropriately. While the issue of iron overload
has been raised, this is rarely a practical clinical con-
cern, because iron overload is a long-term process and
is uncommon other than in hemochromatosis. More-
over, the majority of the world’s population is iron de-
ficient [32, 33] and the amount of iron available for
physiologic use is tightly regulated [34, 35]. Neverthe-
less, careful screening and appropriate candidate se-
lection are encouraged.
Conclusions
FE-HASTE imaging provides a simple, fast, and reliable
strategy for uniform, flow independent blood signal sup-
pression at 3 T and 1.5 T. Compared to pre-contrast
HASTE, FE-HASTE obviates the need for magnetization
preparation schemes and ECG gating, which add com-
plexity and may limit achievable resolution. In those
already undergoing clinical FE-CMR for bright-blood ap-
plications, black-blood FE-HASTE is a simple and prac-
tical technique that can be used in conjunction with
bright-blood imaging for further characterization of car-
diovascular pathology.
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